{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:16Z","timestamp":1792425736957,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["602420"],"award-info":[{"award-number":["602420"]}],"id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.expneurol.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T11:06:02Z","timestamp":1551870362000},"page":"133-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis"],"prefix":"10.1016","volume":"317","author":[{"given":"Maartje G.","family":"Huijbers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"Plomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge E.","family":"van Es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne E.","family":"Filli\u00e9-Grijpma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Kamar-Al Majidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Ulrichts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"de Haard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silv\u00e8re M.","family":"van der Maarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2019.03.001_bb0005","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0015","doi-asserted-by":"crossref","first-page":"9949","DOI":"10.1523\/JNEUROSCI.3169-05.2005","article-title":"Identification of nicotinic acetylcholine receptor recycling and its role in maintaining receptor density at the neuromuscular junction in vivo","volume":"25","author":"Bruneau","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0020","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4161\/mabs.25439","article-title":"Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis","volume":"5","author":"Challa","year":"2013","journal-title":"Mabs"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/jn.1998.80.1.365","article-title":"Spontaneous electromyographic activity in adult rat soleus muscle","volume":"80","author":"Eken","year":"1998","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0040","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nyas.13518","article-title":"Myasthenia gravis with antibodies to MuSK: an update","volume":"1412","author":"Evoli","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0055","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jps.20297","article-title":"Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions","volume":"94","author":"Getman","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0060","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1113\/jphysiol.2013.270207","article-title":"Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction","volume":"592","author":"Ghazanfari","year":"2014","journal-title":"J. Physiol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0065","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0075","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0085","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","article-title":"Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity","volume":"291","author":"Huijbers","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0105","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jca.21222","article-title":"Anticoagulation techniques in apheresis: from heparin to citrate and beyond","volume":"27","author":"Lee","year":"2012","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0125","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0036-1584322","article-title":"The Immunobiology of immunoglobulin G4","volume":"36","author":"Lighaam","year":"2016","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0130","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.4049\/jimmunol.178.8.5390","article-title":"Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade","volume":"178","author":"Liu","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","article-title":"Efficacy of intravenous immunoglobulin in neurological diseases","volume":"13","author":"Lunemann","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2016.03.007","article-title":"A comprehensive review of the neonatal Fc receptor and its application in drug delivery","volume":"161","author":"Martins","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0145","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0150","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1073\/pnas.0708960105","article-title":"Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn","volume":"105","author":"Mezo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0155","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.expneurol.2012.06.034","article-title":"Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors","volume":"237","author":"Morsch","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jnnp.2006.102517","article-title":"Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands","volume":"78","author":"Niks","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0165","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00176","article-title":"Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates","volume":"6","author":"Nixon","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jca.20247","article-title":"Introduction and overview of therapeutic apheresis","volume":"25","author":"Okafor","year":"2010","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0185","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4049\/jimmunol.1003780","article-title":"Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model","volume":"187","author":"Patel","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0190","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.expneurol.2015.01.007","article-title":"Electrophysiological analysis of neuromuscular synaptic function in myasthenia gravis patients and animal models","volume":"270","author":"Plomp","year":"2015","journal-title":"Exp. Neurol."},{"issue":"48","key":"10.1016\/j.expneurol.2019.03.001_bb0200","first-page":"2","article-title":"Abnormally short serum half-lives of chimeric and human IgGs in NOD-SCID mice","volume":"190","author":"Pop","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0205","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.expneurol.2011.04.018","article-title":"Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice","volume":"230","author":"Punga","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0210","first-page":"15","article-title":"Phase II, multiple-dose study of anti-FcRn antibody, Rozanolixizumab (UCB7665), in patients with primary immune thrombocytopenia: interim analysis","volume":"130","author":"Robak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0220","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0225","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0230","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","article-title":"Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice","volume":"154","author":"Shultz","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fimmu.2015.00011","article-title":"On the dark side of therapies with immunoglobulin concentrates: the adverse events","volume":"6","author":"Spath","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0250","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0255","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic fab arm exchange","volume":"317","author":"van der Neut","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2019.03.001_bb0260","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0265","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/1061186X.2013.875030","article-title":"Neonatal fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering","volume":"22","author":"Wang","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0270","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jid.2018.03.546","article-title":"FcRn blockade with SYNT001 for the treatment of pemphigus","volume":"138","author":"Werth","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.expneurol.2019.03.001_bb0275","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1242\/dev.038711","article-title":"To build a synapse: signaling pathways in neuromuscular junction assembly","volume":"137","author":"Wu","year":"2010","journal-title":"Development"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488618305752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488618305752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T14:09:35Z","timestamp":1739801375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488618305752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":54,"alternative-id":["S0014488618305752"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.03.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735292286.793567823","asserted-by":"object"}]},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}